1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGP acyltransferase 2; 1-AGPAT 2; Lysophosphatidic acid acyltransferase beta; LPAAT-beta; AGPAT2

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Antigen Affinity Purified

Liquid

Shipped at 4 degree C. Upon delivery aliquot and store at -20 degree C or -80 degree C. Avoid repeated freeze.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of anti-AGPAT2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone.

ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)

Western blot
All lanes: AGPAT2 antibody at 1.09ug/ml+Jurkat whole cell lysate
Secondary
Goat polyclonal to rabbit at 1/10000 dilution
Predicted band size: 31,28 kDa
Observed band size: 31 kDa

Immunohistochemistry of paraffin-embedded human small intestine tissue using MBS7044678 at dilution 1:100

Immunohistochemistry of paraffin-embedded human skin tissue using MBS7044678 at dilution 1:100

27,279 Da

1-acylglycerol-3-phosphate O-acyltransferase 2

1-acyl-sn-glycerol-3-phosphate acyltransferase beta

1-acyl-sn-glycerol-3-phosphate acyltransferase beta

1-AGP acyltransferase 2; 1-AGPAT 2; LPAAT-beta??[Similar Products]

PLCB_HUMAN

This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]

AGPAT2: Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Defects in AGPAT2 are the cause of congenital generalized lipodystrophy type 1 (CGL1); also known as Berardinelli-Seip congenital lipodystrophy type 1 (BSCL1) or Berardinelli-Seip syndrome. CGL1 is an autosomal recessive disorder characterized by marked paucity of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Belongs to the 1-acyl-sn-glycerol-3-phosphate acyltransferase family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Transferase; Lipid Metabolism - ether lipid; Membrane protein, multi-pass; Lipid Metabolism - glycerolipid; Membrane protein, integral; EC 2.3.1.51; Lipid Metabolism - glycerophospholipid

Chromosomal Location of Human Ortholog: 9q34.3

Cellular Component: endoplasmic reticulum; endoplasmic reticulum membrane

Molecular Function: 1-acylglycerol-3-phosphate O-acyltransferase activity

Biological Process: phosphatidic acid biosynthetic process; positive regulation of cytokine and chemokine mediated signaling pathway; positive regulation of cytokine production; triacylglycerol biosynthetic process

Disease: Lipodystrophy, Congenital Generalized, Type 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.